01 AI-Enabled Quality Control in Blood Component Processing The growing volume of blood components handled by transfusion centers is increasing the value of AI-enabled quality control, with machine learning tools supporting automated monitoring of component quality, process deviations, and storage conditions; recent research has identified AI applications across blood component processing and quality management, including predictive error detection and statistical process control.
02 Shift Toward Automated Blood Component Processing Operational pressure to improve consistency and reduce manual handling is shifting blood component processing toward automated systems, where centrifugation, separation, weighing, labeling, and component preparation can be integrated into standardized workflows; automated blood component processing systems can process multiple units with reduced operator intervention, supporting more consistent preparation and traceability.
01 Increasing Prevalence of Blood Disorders and Expansion of Cancer Treatment Services Drive Market The rising prevalence of blood disorders increases demand for regular transfusions and blood components, particularly among patients requiring long-term supportive care. Conditions such as thalassemia and sickle cell disease can require repeated red blood cell transfusions to manage anemia and maintain adequate oxygen supply. For example, patients with transfusion-dependent thalassemia may require scheduled blood transfusions throughout their lives. The growing patient population therefore increases recurring demand for screened blood, red blood cells, and other transfusion components.The expansion of cancer treatment services increases demand for blood components because chemotherapy and hematopoietic stem-cell transplantation can reduce blood cell and platelet levels. Patients with leukemia and other blood cancers may require transfusions to manage anemia or low platelet counts during treatment. For example, platelet and red blood cell transfusions are commonly used to support patients undergoing intensive cancer treatment. Growing oncology capacity therefore increases hospital requirements for reliable blood inventories and supports demand across transfusion services.
01 Shortage of Blood Donors and Low Voluntary Blood Donation Rates in Some Regions Restrain Market Expansion An insufficient donor pool can reduce the availability of whole blood and blood components needed for transfusion services. Limited supply can create shortages during periods of high clinical demand and increase pressure on blood collection and inventory management. This constraint can delay transfusion procedures and limit the capacity of healthcare facilities to meet patient requirements.Low participation in voluntary blood donation can restrict the regular replenishment of blood inventories, particularly in regions with limited donor awareness or established collection infrastructure. Irregular donations can create gaps between blood demand and available supplies and increase dependence on replacement or emergency donations. These supply constraints can limit access to transfusion services and slow market expansion.
01 Expansion of Blood Plasma-Derived Products and Growth of Point-of-Care Blood Testing Offer Growth Opportunities Plasma processors and pharmaceutical companies can target demand for albumin, immunoglobulins, and clotting-factor therapies derived from collected plasma. Companies such as CSL Behring and Takeda can expand revenue through plasma-derived product portfolios, processing capacity, and supply partnerships. Higher-value plasma applications can also improve revenue generation from each collected plasma unit.Hospitals, blood banks, and diagnostic providers can adopt rapid systems for blood typing and compatibility testing near the point of transfusion. Companies such as Abbott and QuidelOrtho can create additional revenue through portable analyzers, testing platforms, and recurring consumable sales. Decentralized testing can also create demand for compact systems across smaller hospitals and transfusion centers.
01 Increasing Demand for Specialized Blood Components and Complexity of Maintaining Cold-Chain Logistics Hinders Growth Growing use of cancer treatment, organ transplantation, trauma care, and complex surgeries increases demand for specific components such as platelets and plasma. For example, hematological cancer patients undergoing chemotherapy may require repeated platelet transfusions, placing additional pressure on component inventories and distribution networks.Blood components require controlled storage and transportation conditions, making reliable temperature management essential across collection, processing, storage, and delivery. For example, WHO identifies inadequate blood-storage and transportation systems as a challenge in low-resource settings, where cold-chain gaps can increase component losses and restrict expansion of transfusion services.
March 2026 Blood transfusion technology companies continued expanding digital blood management solutions to improve traceability, inventory management, and transfusion safety. Healthcare organizations increasingly adopted integrated software platforms that support blood component tracking, donor information management, and hospital transfusion workflows.
February 2026 Haemonetics expanded its blood management technology portfolio through continued advancement of transfusion information systems and blood component management solutions. The company focused on improving operational efficiency for blood centers and hospitals through digital tools supporting collection, processing, storage, and transfusion processes.
January 2026 Fresenius Kabi continued strengthening its transfusion medicine portfolio through advancements in blood collection, separation, and cell processing technologies. The company focused on improving efficiency and safety across blood component preparation and therapeutic procedures.
December 2025 Grifols expanded its transfusion diagnostics capabilities through continued development and commercialization of automated blood grouping and antibody testing systems. The company focused on improving accuracy and efficiency in immunohematology laboratories supporting transfusion compatibility testing.